Drug Database
DT

DTaP-IPV-HB-PRP-T vaccine (Hexacima / Hexaxim / Hexyon)

✓ Approved

Merck & Co. · 疫苗 · 疫苗

什么是 DTaP-IPV-HB-PRP-T vaccine?

DTaP-IPV-HB-PRP-T vaccine 是一种疫苗,由Merck & Co.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection、Intravenous (IV)。

药物档案

商品名Hexacima, Hexaxim, Hexyon
公司Merck & Co.
药物类别疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection, Intravenous (IV)
状态Approved

治疗适应症

DTaP-IPV-HB-PRP-T vaccine 针对 5 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsDiphtheria✓ Approved
Infections and infestationsHepatitis B✓ Approved
Infections and infestationsPertussis✓ Approved
Infections and infestationsTetanus✓ Approved
Surgical and medical proceduresPolio immunisation✓ Approved

相关研究文献

PubMedBioinformatics and biology insights2026-11-18

Formulation of a Novel NS5A- and NS5B-Based Chimeric Vaccine Against Hepatitis C Virus: An Artificial Intelligence-Supported Approach.

Niknam Maryam M, Zohrabzadeh Maryam M, Hahashempour Ava A, Honari Jahromi Ali A et al.

We aimed to design a multiepitope vaccine against hepatitis C virus (HCV) with the potential to elicit broad protective immunity against diverse HCV genotypes through computational design.Method: One hundred sequences of the most widespread subtypes of HCV were retrieved from the Los Alamos National Laboratory database, and consensus sequences of the NS5A and NS5B proteins were generated to construct an efficient vaccine for human use. Numerous B-cell lymphocyte, cytotoxic T-lymphocyte and helper T-lymphocyte epitopes located in the conserved domains of HCV proteins and similar in human and mouse alleles were evaluated criteria for use in the vaccine construct. Population coverage analysis identified that substantial parts of the worldwide population carry epitopes and their corresponding alleles within their genome, which confirms that the vaccine candidate is an effective agent against this lethal disease. Codon optimization and in silico cloning of eukaryotic and prokaryotic vectors validated the strong expression of the vaccine construct in the host systems. Molecular docking analysis revealed favorable binding affinities between the vaccine construct and toll-like receptors, which confirmed the vaccine's capacity to induce robust and stable immune responses against the hepatitis C virus. We incorporated new bioinformatic methods to design multiepitope vaccine against HCV. The development of a vaccine targeting multi genotypes of HCV could potentially provide for long-term protection against infection and may mitigate the risk of drug resistance across various genotypes and subtypes. Current research emphasizes the need for a vaccine that can elicit comprehensive immune responses, including both neutralizing antibodies and T-cell responses, to effectively address the genetic diversity of the virus. Future experimental studies are essential to validate predicted immunogenicity, structural stability, and protective efficacy before clinical consideration.

PMID 43047676
阅读全文 →
PubMedAnalytical chemistry2026-11-18

Regulating Blood Cell Lateral Migration for High Performance Platelet-Rich Plasma Separation.

Zheng Kai K, Liu Zhaomiao Z, Pang Lu L, Zhao Siyu S et al.

Platelet-rich plasma (PRP) has broad therapeutic potential, yet current separation methods remain challenged by the trade-off between platelet (PLT) concentration, purity, and activation status. Here, we develop a microfluidic strategy for PRP separation by integrating lateral migration regulation with gravitational settling of blood cells. We demonstrate that microchannel architecture modifies the secondary-flow structure within the settling chamber, thereby regulating the lateral migration of blood cells. Compared with a discrete settling chamber, a continuous settling chamber provides a longer settling path, facilitating PLT enrichment and blood cell separation. Simulations of the microchannel structural unit demonstrated preferential settling of WBCs and RBCs, while PLTs remained largely suspended. Across the tested operating conditions, the PRP chip achieved a maximum PLT enrichment ratio of 4.6 and a maximum purity of 94%. Compared with conventional centrifugation, PRP produced by the chip exhibited lower platelet activation, as evidenced by a lower CD62P-positive platelet fraction and lower platelet-activating factor concentrations. Comprehensive evaluation of PLT activation and PRP composition identified a Reynolds number range of 50-100 as optimal for the PRP chip.

PMID 43046484
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Efficacy of Oxygen-Enriched Platelet-Rich Plasma Combined With Minoxidil in the Treatment of Androgenetic Alopecia: A Retrospective Study.

Lu Jianyun J, Zhang Tong T, Wang Dan D, Zhou Lu L et al.

Androgenetic alopecia (AGA) is a common disorder that negatively affects quality of life. Platelet-rich plasma (PRP) has shown efficacy in hair regeneration. Ozone treatment amplifies the biological effects of PRP, thereby strengthening its role in follicular regeneration. To evaluate the efficacy and safety of oxygen-enriched PRP combined with 5% minoxidil compared with minoxidil monotherapy in AGA. In this retrospective comparative study, treatment of 72 patients was reviewed. Patients were categorized according to the treatment they had received: oxygen-enriched PRP combined with minoxidil or minoxidil monotherapy. The combination group received 5 PRP injection sessions at two-week intervals with daily topical minoxidil, while the control group used minoxidil alone. Efficacy was assessed by dermoscopic parameters and satisfaction scores; adverse events were recorded. The combination group showed significantly greater improvements in hair density, hair diameter, and follicular density compared with monotherapy (p < 0.05). No significant differences were observed in terminal hair ratio or mean number of hairs per follicular unit (p > 0.05). Patient and physician reported satisfaction scores were higher in the combination group. Adverse events were mild and transient, with no serious complications. Oxygen-enriched PRP combined with minoxidil is more effective than minoxidil alone for improving hair growth parameters and patient satisfaction. These findings support ozone-treated PRP as a promising therapy for AGA.

PMID 43047183
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Ophthalmic Vascular Occlusion and Blindness After Platelet-Rich Plasma Injections: A Systematic Review.

Ebrahimzade Mandana M, Nazari Shahriar S, Pourani Mohammad Reza MR, Muñoz-Gonzalez Cristina C et al.

Platelet-rich plasma (PRP) is widely used in aesthetic and regenerative medicine; however, rare vision-threatening complications such as blindness have been reported following facial injections. This systematic review aimed to identify and analyze all published cases of visual impairment following PRP injections. A systematic literature search was performed until August 2025, using PubMed, Embase, and Scopus, supplemented by a manual Google Scholar search. Search terms combined "platelet-rich plasma" with ophthalmic complications. Case reports describing visual impairment after PRP injection were included without date or language restrictions. Data extracted included patient demographics, indication, injection site, onset and pattern of vision loss, ophthalmologic findings, management, and outcome. Seven articles reporting 10 cases of PRP-associated unilateral visual loss published between 2017 and 2025 were identified. All patients were female (22-64 years). Most cases (n = 9) followed PRP injections for facial rejuvenation, predominantly in the glabella (n = 6) and forehead (n = 4), while one followed scalp PRP for alopecia. Vision loss was immediate and painful in 9 cases; 8 presented with no light perception. Two cases with delayed or partial visual impairment demonstrated visual recovery after corticosteroid therapy. Fundoscopic findings indicated retinal and choroidal ischemia. Although rare, PRP injections can cause irreversible blindness, likely due to embolic ophthalmic artery occlusion (OAO). Prevention through safe injection technique is essential, as treatment options remain limited and often ineffective. Over half of the reported cases were performed by non-physicians or inadequately trained practitioners, underscoring the critical need for proper credentials and training.

PMID 43047023
阅读全文 →
PubMedLangenbeck's archives of surgery2026-11-18

Comparing the effect of intra-articular injection of platelet-rich plasma (PRP) with corticosteroids on the treatment of osteonecrosis of the femoral head.

Zandrahimi Farshad F, Dousari Amin Sadeghi AS, Hashemian Morteza M, Farzan Abdolmajid A et al.

Osteonecrosis of the femoral head is a common orthopedic problem that mainly affects young people. The main causes of this disease include the use of steroid drugs, some medications, and trauma to the joint. According to the Ficot classification, this disease is divided into four stages, and the more advanced the stage, the more extensive intervention is required. In the early stages, methods such as core decompression and the use of platelet-rich plasma (PRP) are recommended to improve the results. This study aims to evaluate and compare the effectiveness of two treatment methods, PRP and corticosteroid injection, in improving the clinical and radiological symptoms of patients with osteonecrosis of the femoral head. This is a retrospective case-control study in which patients aged 18 to 70 years with a diagnosis of stage 1 or 2 osteonecrosis of the femoral head based on MRI referred to the orthopedic clinic of Shahid Bahonar Hospital, Kerman, Iran, were studied. Based on the treatment received, the patients were categorized into two groups: PRP injection and corticosteroid injection. Patients will be evaluated using MRI, modified Kerboul angle, Harris Hip Score, Foot Health Questionnaire (FSHQ-Br), and McGill Pain Questionnaire (MPQ) at specific time intervals. The results will be analyzed using statistical tests and the significance level is considered less than 0.05. 64 patients with osteonecrosis of the femoral head participated in this study. This study showed that both PRP and corticosteroids are effective in improving symptoms and function in patients with osteonecrosis of the femoral head, although PRP had better long-term results. Corticosteroids showed more immediate pain relief and improved function in the short term (3 months), while PRP provided more sustained improvement in all evaluated outcomes at 6 months. In addition, PRP showed a significant reduction in radiological progression of osteonecrosis compared with corticosteroids. These findings are consistent with the existing evidence of beneficial effects of PRP on angiogenesis, osteogenesis, and inhibition of inflammation in the treatment of osteonecrosis of the femoral head. The results of this study indicated that the selection of optimal treatment should be based on a comprehensive assessment of each patient's clinical status, preferences, and treatment goals. Overall, PRP may be a promising treatment option to improve outcomes and quality of life in patients with osteonecrosis of the femoral head.

PMID 43045812
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Comparing the Efficacy and Safety of PRP and PRF on Periorbital Skin Quality: A Randomized Split-Face Clinical Trial.

Behrangi Elham E, Zeinali Roya R, Zare Sona S, Dehghani Abbas A et al.

Infraorbital area significantly affects perceived age and patient quality of life. Although regenerative treatments such as platelet-rich plasma (PRP) are widely used for under-eye, evidence comparing PRP with platelet-rich fibrin (PRF) is limited. This study aims to compare PRP to PRF for periorbital area. In this clinical trial, each participant randomly received PRP on one side and PRF on the contralateral side in three sessions. A tear-trough-based approach with sandwich technique was utilized. Outcomes were assessed at baseline, 3, 4, and 7 months using biometric indices (TEWL, melanin, erythema, elasticity parameters, colorimeter), standardized grading scales (hyperpigmentation, wrinkles, and hollowness, patient satisfaction scores), and ultrasonography. Statistical analysis was conducted with significance set at p < 0.05. Twenty-four patients completed the study (mean age 40.71 ± 10.9 years; 95.8% female). TEWL and colorimeter decreased in both groups, without statistically significant differences between groups (p > 0.05). Melanin and erythema demonstrated a consistent decreasing trend in the PRF group beginning at Month 3, whereas both indices paradoxically increased at Month 3 in the PRP group before declining thereafter. Sonographic parameters, POH grade, wrinkle grade at 3 and 4 months, and Allergan grade at 4 months improved significantly in both groups (p < 0.05), with no significant differences between groups. Patient satisfaction increased in both groups and reached statistical significance between Months 3 and 4 (p = 0.037). Both treatments were tolerated, with no major adverse effects. Both PRP and PRF significantly improved periorbital hyperpigmentation, fine wrinkles, and mild hollowness. PRF demonstrated more stable reduction in melanin and erythema and showed earlier improvement in certain elasticity parameters. Neither treatment provided sufficient correction for severe hollowness. Repeated sessions every 3-4 months may be required to maintain results. Iranian Registry of Clinical Trials (IRCT): IRCT20200127046282N51.

PMID 43046986
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多DTaP-IPV-HB-PRP-T vaccine